[
    [
        {
            "time": "2019-07-31",
            "original_text": "Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie",
            "features": {
                "keywords": [
                    "Allergan",
                    "Boosts",
                    "Guidance",
                    "AbbVie"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Allergan beats second-quarter expectations, boosts full-year guidance",
            "features": {
                "keywords": [
                    "Allergan",
                    "beats",
                    "second-quarter",
                    "expectations",
                    "guidance"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan beats second-quarter expectations, boosts full-year guidance",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up",
            "features": {
                "keywords": [
                    "Allergan",
                    "Q2",
                    "Earnings",
                    "Sales",
                    "Top",
                    "View",
                    "Up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Despite Historic Market Performance, IMX Remains Relatively Unchanged",
            "features": {
                "keywords": [
                    "Historic",
                    "Market",
                    "Performance",
                    "IMX",
                    "Unchanged"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "market_index"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Despite Historic Market Performance, IMX Remains Relatively Unchanged",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Top Research Reports: Chevron, AbbVie, Phillips 66 & More",
            "features": {
                "keywords": [
                    "Research",
                    "Reports",
                    "Chevron",
                    "AbbVie",
                    "Phillips",
                    "66"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Research Reports: Chevron, AbbVie, Phillips 66 & More",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand",
            "features": {
                "keywords": [
                    "Allergan",
                    "profit",
                    "revenue",
                    "forecast",
                    "Restasis",
                    "Juvederm",
                    "demand"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal",
            "features": {
                "keywords": [
                    "Allergan",
                    "Tops",
                    "Q2",
                    "Profit",
                    "Estimate",
                    "Lifts",
                    "Revenue",
                    "Guidance",
                    "Abbive",
                    "Deal"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]